This page was printed from the Northern & Eastern Devon Formulary and Referral site at
Please ensure you are using the current version of this document
This is a summary of the NEW Devon CCG commissioning policy for Dupuytren's contracture treatment
Medical treatment for Dupuytren's contracture with collagenase clostridium histolyticum (Xiapex®) is commissioned in accordance with National Institute for Health and Care Excellence (NICE) Technology Appraisal guidance 459.
Surgical treatment for Dupuytren's contracture will be routinely commissioned in Devon in the following circumstances:
Significant functional impairment is defined as a loss or absence of an individual's capacity to meet personal, social or occupational demands.
Where the circumstances of treatment for an individual patient do not meet the criteria described above exceptional funding can be sought. Individual cases will be reviewed by the appropriate panel of the CCG upon receipt of a completed application from the patient's GP, consultant or clinician. Applications cannot be considered from patients personally.
Publication date: Updated September 2017